Rosetta Genomics Announces NGS Research Collaboration with Weizmann Institute
News Aug 01, 2014
Rosetta Genomics Ltd. has announced that the Company has entered into a collaborative research and license agreement with Yeda Research and Development Co. Ltd., the commercial arm of the Weizmann Institute of Science.
The agreement involves collaboration with the Nancy and Stephen Grand Israel National Center for Personalized Medicine to develop novel methods for the preparation of next-generation sequencing libraries for small RNAs.
The initial goals of this collaboration are to make this type of sequencing more cost effective as well as to minimize sequence-specific biases. The collaboration also aims at developing computational methods required for data analysis.
The potential developed methods could allow more accurate quantification of microRNAs in various biological samples and pathological conditions.
"We are very pleased to be working with the Weizmann Institute of Science on these important programs. The Weizmann Institute is one of the world's leading multidisciplinary research institutes, and the source of numerous groundbreaking medical discoveries and technological applications. Working in collaboration with the Institute provides us with the world-class infrastructure needed to pursue breakthroughs in sequencing and data analysis," stated Kenneth A. Berlin, Rosetta President and Chief Executive Officer.
Berlin continued, "The major advantages of next-generation sequencing for microRNA profiling are detection of both novel and known microRNAs and precise identification of microRNA sequences. These advances will allow us to incorporate sequencing in more of our projects, thereby enhancing our capabilities to more cost-effectively and accurately develop powerful, new diagnostic products with significant clinical utility."
Some MRSA infections could be tackled using widely-available antibiotics, suggests new research. A team of scientists used genome sequencing technology to identify which genes make MRSA susceptible to a previously defined combination of drugs. They identified a number of mutations centered around a protein known as a penicillin-binding protein 2a or PBP2a.